China Begins Human Trial for First COVID-19 Nasal Spray Vaccine
By HospiMedica International staff writers Posted on 14 Sep 2020 |
Image: China Begins Human Trial for First COVID-19 Nasal Spray Vaccine (Photo courtesy of University of Hong Kong)
China has approved a nasal spray COVID-19 vaccine candidate for clinical trial in humans that could be more effective in stopping the spread of the coronavirus through the respiratory tracts and serve as an alternative to painful injections.
The nasal spray vaccine candidate against COVID-19 has been developed by the State Key Laboratory for Emerging Infectious Diseases of the University of Hong Kong (Pokfulam, Hong Kong) in partnership with the Xiamen University (Fujian, China) and Beijing Wantai Biological Pharmacy Enterprise Co. (Beijing, China).
The nasal spray vaccine candidate against COVID-19 is based on the established flu-based DelNS1 live attenuated influenza virus (LAIV) platform with the deletion of the key virulent element and immune antagonist, NS1, from the viral genome and is potentially more immunogenic than wild type influenza virus. The vaccine strategy has been selected as one of the five vaccine technologies by the Ministry of Science and Technology of China for further evaluation.
The flu-based vaccine can be combined with any seasonal flu vaccine strains, and can be produced in chicken embryonated eggs and MDCK cells which are proven production systems for influenza vaccines. Its features are highly safe and it is used as nasal spray to induce specific immunity in the airway of humans. The flu-based COVID-19 vaccine has been approved for clinical trial in humans by China’s National Medical Products Administration (NMPA), making it the first nasal spray COVID-19 vaccine to be tested in humans.
Related Links:
University of Hong Kong
Xiamen University
Beijing Wantai Biological Pharmacy Enterprise Co.
The nasal spray vaccine candidate against COVID-19 has been developed by the State Key Laboratory for Emerging Infectious Diseases of the University of Hong Kong (Pokfulam, Hong Kong) in partnership with the Xiamen University (Fujian, China) and Beijing Wantai Biological Pharmacy Enterprise Co. (Beijing, China).
The nasal spray vaccine candidate against COVID-19 is based on the established flu-based DelNS1 live attenuated influenza virus (LAIV) platform with the deletion of the key virulent element and immune antagonist, NS1, from the viral genome and is potentially more immunogenic than wild type influenza virus. The vaccine strategy has been selected as one of the five vaccine technologies by the Ministry of Science and Technology of China for further evaluation.
The flu-based vaccine can be combined with any seasonal flu vaccine strains, and can be produced in chicken embryonated eggs and MDCK cells which are proven production systems for influenza vaccines. Its features are highly safe and it is used as nasal spray to induce specific immunity in the airway of humans. The flu-based COVID-19 vaccine has been approved for clinical trial in humans by China’s National Medical Products Administration (NMPA), making it the first nasal spray COVID-19 vaccine to be tested in humans.
Related Links:
University of Hong Kong
Xiamen University
Beijing Wantai Biological Pharmacy Enterprise Co.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans